Regulatory watch: impact of PDUFA on regulatory decision-making.
作者信息
Hay Michael
出版信息
Nat Rev Drug Discov. 2010 Aug;9(8):585. doi: 10.1038/nrd3247.
DOI:10.1038/nrd3247
PMID:20671755
Abstract
摘要
相似文献
1
Regulatory watch: impact of PDUFA on regulatory decision-making.
Nat Rev Drug Discov. 2010 Aug;9(8):585. doi: 10.1038/nrd3247.
2
The Prescription Drug User Fee Act: is a faster Food and Drug Administration always a better Food and Drug Administration?
Food Drug Law J. 2005;60(2):261-338.
3
PDUFA reauthorization--drug safety's golden moment of opportunity?
N Engl J Med. 2007 Apr 26;356(17):1703-4. doi: 10.1056/NEJMp078048. Epub 2007 Apr 13.
4
The Prescription Drug User Fee Act of 1992: speeding up the drug approval process.
Healthspan. 1992 Dec;9(11):12-4.
5
FDA and drug safety: new Tufts study challenges critics of the Prescription Drug User Fee Act.
J Law Med Ethics. 2006 Spring;34(1):131-4. doi: 10.1111/j.1748-720X.2006.00018.x.
6
Paying for drug approvals--who's using whom?
N Engl J Med. 2007 Apr 26;356(17):1697-700. doi: 10.1056/NEJMp078041. Epub 2007 Apr 13.
7
What ails the FDA?
N Engl J Med. 2005 Mar 17;352(11):1063-6. doi: 10.1056/NEJMp058003.
8
Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars.
Seton Hall Law Rev. 2011;41(2):559-92.
9
Drug safety reform at the FDA--pendulum swing or systematic improvement?
N Engl J Med. 2007 Apr 26;356(17):1700-2. doi: 10.1056/NEJMp078057. Epub 2007 Apr 13.
10
A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
Suffolk Univ Law Rev. 2003;36(3):787-819.
Zotero 插件